ClinVar Miner

Submissions for variant NM_000277.3(PAH):c.463C>T (p.Arg155Cys)

gnomAD frequency: 0.00002  dbSNP: rs539743701
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen PAH Variant Curation Expert Panel RCV000669560 SCV001448615 likely pathogenic Phenylketonuria 2020-10-15 reviewed by expert panel curation This c.463C>T (p.Arg155Cys) variant in PAH was reported in at least one patient with mild HPA detected in trans with pathogenic variant p.Gly289Arg (PMID: 27121329). A defect in the synthesis or regeneration pathways of 6R-BH4 was ruled out by analyzing urinary pterin levels as well as by measuring the dihydropteridine reductase activity. Computational evidence supports a deleterious effect. This variant is observed at an amino acid residue where two other pathogenic missense variants have also been observed. This variant is seen at an extremely low frequency in population databases. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM5, PM3, PM2, PP4_moderate, and PP3.
Counsyl RCV000669560 SCV000794323 uncertain significance Phenylketonuria 2017-11-14 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000669560 SCV001574358 pathogenic Phenylketonuria 2023-08-10 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg155 amino acid residue in PAH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 18937047, 23932990, 24401910, 26210745, 28754886). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PAH protein function. ClinVar contains an entry for this variant (Variation ID: 554011). This missense change has been observed in individual(s) with phenylketonuria (PMID: 23514811). This variant is present in population databases (rs539743701, gnomAD 0.006%). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 155 of the PAH protein (p.Arg155Cys).
Fulgent Genetics, Fulgent Genetics RCV000669560 SCV002815715 pathogenic Phenylketonuria 2021-09-06 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000669560 SCV002819565 likely pathogenic Phenylketonuria 2022-12-15 criteria provided, single submitter clinical testing Variant summary: PAH c.463C>T (p.Arg155Cys) results in a non-conservative amino acid change located in the Aromatic amino acid hydroxylase, C-terminal domain (IPR019774) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251344 control chromosomes. c.463C>T has been reported in the literature in individuals affected with Phenylalanine Hydroxylase Deficiency (Phenylketonuria; Bueno_2013, Aldamiz-Echevarria_2016, Hillert_2020). Two other variants affecting the same amino acid have been reported in association with Phenylketonuria in HGMD (R155H, R155P). Two clinical diagnostic laboratories and one expert panel have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation: two submitters classified the variant as VUS and pathogenic, respectively while the ClinGen PAH Variant Curation Expert Panel classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Baylor Genetics RCV000669560 SCV004209621 pathogenic Phenylketonuria 2024-03-26 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000669560 SCV004237396 pathogenic Phenylketonuria 2023-06-08 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.